The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s intratumoral cancer therapies market report forecasts the intratumoral cancer therapies market size to grow to $197.86 Billion by 2027, with a CAGR (compound annual growth rate) of more than 12%.

Learn More On The Intratumoral Cancer Therapies Market Report 2023 – https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report

Intratumoral Cancer Therapies Market Size Forecast
The global intratumoral cancer therapies market is expected to grow from $109.66 billion in 2022 to $124.82 billion in 2023 at a compound annual growth rate (CAGR) of 13.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global intratumoral cancer therapies market size is expected to reach $197.86 billion in 2027 at a CAGR of 12.2%.

North America held the largest intratumoral cancer therapies market share.

Key Intratumoral Cancer Therapies Market Driver ­– Increase In The Incidence Of Cancer
According to the World Cancer Fund Research International, a UK-based non-profit organisation dedicated to cancer prevention, there will be 18,094,716 million new cases of cancer worldwide in 2020. Furthermore, the International Diabetes Federation, an organisation comprised of over 230 national diabetes organisations from over 160 nations and territories, predicted that there would be 643 million diabetics globally by 2030, rising to 783 million by 2045. As a result, the rising cancer incidence is propelling the intratumoral cancer therapies market forward.

Request for A Sample Of The Global Intratumoral Cancer Therapies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9979&type=smp

Key Intratumoral Cancer Therapies Market Trend – Technological Advancement
Companies in the intratumoral cancer therapeutics market are embracing new technologies in order to maintain their market position. For example, in March 2022, Evonik, a US-based speciality chemical manufacturing firm, will launch EUDRATEC® SoluFlow, a breakthrough microparticle technology developed to improve the solubility of active medicinal components in oral pharmaceutical formulations, in cancer therapy. Chemicals that were previously thought to be insoluble can now be employed to manufacture a larger range of oral treatments thanks to this groundbreaking technique.

Intratumoral Cancer Therapies Market Segment
1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines
2) By Application: Lung Cancer, Breast Cancer, Malenoma, Prostate Cancer, Head and Neck Cancer, Other Applications
3) By End Users: Hospitals, Cancer Research Centres, Clinics

Intratumoral Cancer Therapies Market Major Players and Strategies
Major players in the intratumoral cancer therapies market are Amgen Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Celgene Corporation, Takeda Pharmaceutical Company Ltd., GlaxoSmithKline PLC., Ziopharm Oncology Inc., Celldex Therapeutics Inc., and Astellas Pharma Inc.

AstraZeneca, a UK-based, science-driven biopharmaceutical company focused on the development, commercialization, and discovery of prescription medications for oncology and rare disorders, paid $120 million for Neogene Therapeutics Inc. in January 2023. This deal will provide AstraZeneca with additional opportunities in cancer treatment. Neogene Therapeutics Inc is an Amsterdam-based biotechnology research firm that provides a personalised treatment based on TCR genes that target neoantigens found in a patient’s tumour.

The Intratumoral Cancer Therapies Global Market Report 2023 covers regional data on intratumoral cancer therapies market size, intratumoral cancer therapies market trends and drivers, opportunities, strategies, and intratumoral cancer therapies market competitor analysis. The countries covered in the intratumoral cancer therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Intratumoral cancer therapy are those that are injected or administered directly to a tumour. These therapies are intended to selectively target tumour cells and can be used with existing cancer treatments such as chemotherapy and radiation therapy.

View More Reports Related To The Intratumoral Cancer Therapies Market –
Cancer Biologics Global Market Report 2023
Cancer Diagnostics Global Market Report 2023
Cancer Immunotherapy Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: